GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Codexis Inc (NAS:CDXS) » Definitions » 5-Year Yield-on-Cost %

Codexis (Codexis) 5-Year Yield-on-Cost % : 0.00 (As of May. 16, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Codexis 5-Year Yield-on-Cost %?

Codexis's yield on cost for the quarter that ended in Mar. 2024 was 0.00.


The historical rank and industry rank for Codexis's 5-Year Yield-on-Cost % or its related term are showing as below:



CDXS's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.66
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Competitive Comparison of Codexis's 5-Year Yield-on-Cost %

For the Biotechnology subindustry, Codexis's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Codexis's 5-Year Yield-on-Cost % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Codexis's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Codexis's 5-Year Yield-on-Cost % falls into.



Codexis 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Codexis is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5

Codexis  (NAS:CDXS) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Codexis 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of Codexis's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.


Codexis (Codexis) Business Description

Traded in Other Exchanges
Address
200 Penobscot Drive, Redwood, CA, USA, 94063
Codexis Inc is involved in the business of providing enzyme optimization services, commercialization of proteins, and developing biocatalyst products. The firm's products and services include Screening and Evolution services, Enzymes, Screening Kits. It also develops protein engineering and biocatalyst platforms such as Codeevolver, Ketoreductases, Transminases, Imine reductases, etc. The company operates in two business segments namely Performance Enzymes and Novel Biotherapeutics. It generates maximum revenue from the Performance Enzymes segment. Geographically, it derives a majority of revenue from the APAC.
Executives
Byron L Dorgan director C/O CODEXIS, INC., 200 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Kevin Norrett officer: Chief Operating Officer C/O SIERRA ONCOLOGY, INC., 1820 GATEWAY DRIVE, SUITE 110, SAN MATEO CA 94404
Margaret Nell Fitzgerald officer: See Remarks ALLAKOS INC., 825 INDUSTRIAL ROAD, SUITE 500, SAN CARLOS CA 94070
Sriram Ryali officer: Chief Financial Officer C/O EIGER BIOPHARMACEUTICALS, INC., 2155 PARK BLVD., PALO ALTO CA 94306
Stephen George Dilly director, officer: See Remarks C/O SIERRA ONCOLOGY, INC., 1820 GATEWAY DRIVE, SUITE 110, SAN MATEO CA 94404
John J Nicols director, officer: President and CEO ALBEMARLE CORP, 451 FLORIDA ST, BATON ROUGE LA 70801
H Stewart Parker director
Rahul Singhvi director 246 HOLLY DRIVE, CHALFONT PA 18914
Dennis P Wolf director 1101 EAST MEADOW DR, PALO ALTO CA 94303
Patrick Y Yang director C/O GENENTECH INC, 1 DNA WAY,MS 49,ATTN:K.STRAND OR J.BERRY, SOUTH SAN FRANCISCO CA 94080-4990
Bernard J Kelley director
Esther Martinborough director C/O CODEXIS, INC., 200 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Jennifer Aaker director C/O CODEXIS, INC., 200 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Alison Moore director C/O ALLOGENE THERAPEUTICS, INC., 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Thomas R Baruch director 1 LETTERMAN DRIVE, BUILDING C, SUITE CM500, SAN FRANCISCO CA 94129